Survey
Monkeypox Expert Survey: Concerns and Treatment Needs
Ticker(s): SIGA, CMRX, EBS, BVNRYSurvey of 30 Infectious Disease experts
Which of the following best describes your level of concern in response to the Monkeypox Outbreak? Select one.
What barriers, if any, do you see ahead in response to containing the Monkeypox outbreak? Please be specific.
What % of the US population do you anticipate will
likely be vaccinated for Monkeypox in the next ____?
- 6 months
- 1 year
- 5 years
Describe a patient profile that you would likely recommend one of the available Monkeypox vaccines. Please be specific.
Which of
the following vaccines, if any, would you be most likely to recommend for
Monkeypox? Select one.
- Why did you answer the previous question the way you did? Please be specific.
With respect to the US population, what number of cases reported in a week would you consider recommending/wanting widespread vaccination? If you would not ever consider a widespread vaccination, please write ‘NA’.
Do you anticipate the US will need more than 1.6 million JYNNEOS vaccine doses this year? Select one.
Do you anticipate the US will need more than 100 million ACAM2000 vaccine doses? Select one.
Which of the following best describes the importance of the role of antiviral treatments such as Tpoxx (tecovirimat) and/or Tembexa (brincidofovir) in response to Monkeypox? Select one.
Which of the following antiviral treatments, if any, would you be most likely to recommend to treat Monkeypox? Select one.
Looking ahead, what do you anticipate your recommended approach to Monkeypox will be in the next 6 months? Select one.
Lastly, what are your thoughts on threat Monkeypox poses to the US population broadly? Do you have other comments on the vaccine or treatment options you would like to share? Please be specific
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
